These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35856032)

  • 1. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer.
    Wang H; Zhao C; Santa-Maria CA; Emens LA; Popel AS
    iScience; 2022 Aug; 25(8):104702. PubMed ID: 35856032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
    Wang H; Ma H; Sové RJ; Emens LA; Popel AS
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
    Kagihara JA; Andress M; Diamond JR
    Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.
    Wu B; Ma F
    Ther Adv Med Oncol; 2020; 12():1758835920916000. PubMed ID: 32426048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
    Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
    J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
    J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model.
    Ruiz-Martinez A; Gong C; Wang H; Sové RJ; Mi H; Kimko H; Popel AS
    PLoS Comput Biol; 2022 Jul; 18(7):e1010254. PubMed ID: 35867773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer.
    Wang CY; Dai HR; Tan YP; Yang DH; Niu XM; Han L; Wang W; Ma LL; Julku A; Jiao Z
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
    Badve SS; Penault-Llorca F; Reis-Filho JS; Deurloo R; Siziopikou KP; D'Arrigo C; Viale G
    J Natl Cancer Inst; 2022 May; 114(5):664-675. PubMed ID: 34286340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
    Brasó-Maristany F; Sansó M; Chic N; Martínez D; González-Farré B; Sanfeliu E; Ghiglione L; Carcelero E; Garcia-Corbacho J; Sánchez M; Soy D; Jares P; Peg V; Saura C; Muñoz M; Prat A; Vivancos A
    Front Oncol; 2021; 11():710596. PubMed ID: 34616675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
    Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab for the treatment of triple-negative breast cancer.
    Heimes AS; Schmidt M
    Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
    Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
    Fleisher B; Brown AN; Ait-Oudhia S
    Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.